Erytech appoints Alex Dusek as VP of commercial strategy
14 May 2018 -

Erytech Pharma SA (EPA: ERYP) has appointed Alex Dusek as vice president of commercial strategy and member of the executive team, the biopharmaceutical company disclosed on Monday.

Dusek has 25 years of market access, product marketing and sales experience across small biotech start-ups and multi-national pharmaceutical companies.

Before joining Erytech, Dusek served as vice president of commercial strategy at Argos Therapeutics (OTCMKTS: ARGS). There he was responsible for pre-launch planning for the commercial distribution of an advanced cell therapy product.

His previous roles included leading global brand strategy at Bayer HealthCare Pharmaceuticals (ETR: BAYN) for the launch of a first-in-class, rare-disease agent, Adempas (riociguat). He was also United Therapeutics' (NASDAQ: UTHR) first marketing employee, building the company's marketing infrastructure and growing the pulmonary hypertension franchise.

Dusek will be based in the US, joining Erytech's expanding team in Cambridge, Massachusetts.